Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Structural characterization of an activin class ternary receptor complex reveals a third paradigm for receptor specificity.

Goebel EJ, Corpina RA, Hinck CS, Czepnik M, Castonguay R, Grenha R, Boisvert A, Miklossy G, Fullerton PT, Matzuk MM, Idone VJ, Economides AN, Kumar R, Hinck AP, Thompson TB.

Proc Natl Acad Sci U S A. 2019 Jul 30;116(31):15505-15513. doi: 10.1073/pnas.1906253116. Epub 2019 Jul 17.

PMID:
31315975
2.

Protocol of a randomised controlled trial in cardiac surgical patients with endothelial dysfunction aimed to prevent postoperative acute kidney injury by administering nitric oxide gas.

Marrazzo F, Spina S, Zadek F, Lama T, Xu C, Larson G, Rezoagli E, Malhotra R, Zheng H, Bittner EA, Shelton K, Melnitchouk S, Roy N, Sundt TM, Riley WD, Williams P, Fisher D, Kacmarek RM, Thompson TB, Bonventre J, Zapol W, Ichinose F, Berra L.

BMJ Open. 2019 Jul 4;9(7):e026848. doi: 10.1136/bmjopen-2018-026848.

3.

Mutations in GDF11 and the extracellular antagonist, Follistatin, as a likely cause of Mendelian forms of orofacial clefting in humans.

Cox TC, Lidral AC, McCoy JC, Liu H, Cox LL, Zhu Y, Anderson RD, Moreno Uribe LM, Anand D, Deng M, Richter CT, Nidey NL, Standley JM, Blue EE, Chong JX, Smith JD, Kirk EP, Venselaar H, Krahn KN, van Bokhoven H, Zhou H, Cornell RA, Glass IA, Bamshad MJ, Nickerson DA, Murray JC, Lachke SA, Thompson TB, Buckley MF, Roscioli T.

Hum Mutat. 2019 Jun 18. doi: 10.1002/humu.23793. [Epub ahead of print]

PMID:
31215115
4.

The anti-sigma factor MucA of Pseudomonas aeruginosa: Dramatic differences of a mucA22 vs. a ΔmucA mutant in anaerobic acidified nitrite sensitivity of planktonic and biofilm bacteria in vitro and during chronic murine lung infection.

Panmanee W, Su S, Schurr MJ, Lau GW, Zhu X, Ren Z, McDaniel CT, Lu LJ, Ohman DE, Muruve DA, Panos RJ, Yu HD, Thompson TB, Tseng BS, Hassett DJ.

PLoS One. 2019 Jun 3;14(6):e0216401. doi: 10.1371/journal.pone.0216401. eCollection 2019.

5.

Myostatin regulates pituitary development and hepatic IGF1.

Czaja W, Nakamura YK, Li N, Eldridge JA, DeAvila DM, Thompson TB, Rodgers BD.

Am J Physiol Endocrinol Metab. 2019 Jun 1;316(6):E1036-E1049. doi: 10.1152/ajpendo.00001.2019. Epub 2019 Mar 19.

PMID:
30888862
6.

Crystal structure of the WFIKKN2 follistatin domain reveals insight into how it inhibits growth differentiation factor 8 (GDF8) and GDF11.

McCoy JC, Walker RG, Murray NH, Thompson TB.

J Biol Chem. 2019 Apr 19;294(16):6333-6343. doi: 10.1074/jbc.RA118.005831. Epub 2019 Feb 27.

PMID:
30814254
7.

An implicit discontinuous Galerkin method for modeling acute edema and resuscitation in the small intestine.

Thompson TB, Riviere BM, Knepley MG.

Math Med Biol. 2019 Feb 5. doi: 10.1093/imammb/dqz001. [Epub ahead of print]

PMID:
30722029
8.

New Insight Into Hyperemesis Gravidarum and a Potential Role for GDF15.

Walker RG, Thompson TB.

Endocrinology. 2018 Jul 1;159(7):2698-2700. doi: 10.1210/en.2018-00439. No abstract available.

PMID:
29846562
9.

A thumbwheel mechanism for APOA1 activation of LCAT activity in HDL.

Cooke AL, Morris J, Melchior JT, Street SE, Jerome WG, Huang R, Herr AB, Smith LE, Segrest JP, Remaley AT, Shah AS, Thompson TB, Davidson WS.

J Lipid Res. 2018 Jul;59(7):1244-1255. doi: 10.1194/jlr.M085332. Epub 2018 May 17.

10.

Molecular characterization of latent GDF8 reveals mechanisms of activation.

Walker RG, McCoy JC, Czepnik M, Mills MJ, Hagg A, Walton KL, Cotton TR, Hyvönen M, Lee RT, Gregorevic P, Harrison CA, Thompson TB.

Proc Natl Acad Sci U S A. 2018 Jan 30;115(5):E866-E875. doi: 10.1073/pnas.1714622115. Epub 2018 Jan 18.

11.

Structure of the human myostatin precursor and determinants of growth factor latency.

Cotton TR, Fischer G, Wang X, McCoy JC, Czepnik M, Thompson TB, Hyvönen M.

EMBO J. 2018 Feb 1;37(3):367-383. doi: 10.15252/embj.201797883. Epub 2018 Jan 12.

12.

A consensus model of human apolipoprotein A-I in its monomeric and lipid-free state.

Melchior JT, Walker RG, Cooke AL, Morris J, Castleberry M, Thompson TB, Jones MK, Song HD, Rye KA, Oda MN, Sorci-Thomas MG, Thomas MJ, Heinecke JW, Mei X, Atkinson D, Segrest JP, Lund-Katz S, Phillips MC, Davidson WS.

Nat Struct Mol Biol. 2017 Dec;24(12):1093-1099. doi: 10.1038/nsmb.3501. Epub 2017 Nov 13.

13.

Correction: Analysis and identification of the Grem2 heparin/heparan sulfate-binding motif.

Kattamuri C, Nolan K, Thompson TB.

Biochem J. 2017 Apr 24;474(9):1529. doi: 10.1042/BCJ-2016-1050_COR. No abstract available.

PMID:
28439042
14.

Structural basis for potency differences between GDF8 and GDF11.

Walker RG, Czepnik M, Goebel EJ, McCoy JC, Vujic A, Cho M, Oh J, Aykul S, Walton KL, Schang G, Bernard DJ, Hinck AP, Harrison CA, Martinez-Hackert E, Wagers AJ, Lee RT, Thompson TB.

BMC Biol. 2017 Mar 3;15(1):19. doi: 10.1186/s12915-017-0350-1.

15.

Coordinated Proliferation and Differentiation of Human-Induced Pluripotent Stem Cell-Derived Cardiac Progenitor Cells Depend on Bone Morphogenetic Protein Signaling Regulation by GREMLIN 2.

Bylund JB, Trinh LT, Awgulewitsch CP, Paik DT, Jetter C, Jha R, Zhang J, Nolan K, Xu C, Thompson TB, Kamp TJ, Hatzopoulos AK.

Stem Cells Dev. 2017 May 1;26(9):678-693. doi: 10.1089/scd.2016.0226. Epub 2017 Mar 20.

16.

Analysis and identification of the Grem2 heparin/heparan sulfate-binding motif.

Kattamuri C, Nolan K, Thompson TB.

Biochem J. 2017 Mar 8;474(7):1093-1107. doi: 10.1042/BCJ20161050. Erratum in: Biochem J. 2017 Apr 24;474(9):1529.

17.

MuSK is a BMP co-receptor that shapes BMP responses and calcium signaling in muscle cells.

Yilmaz A, Kattamuri C, Ozdeslik RN, Schmiedel C, Mentzer S, Schorl C, Oancea E, Thompson TB, Fallon JR.

Sci Signal. 2016 Sep 6;9(444):ra87. doi: 10.1126/scisignal.aaf0890.

18.

Structure of Gremlin-2 in Complex with GDF5 Gives Insight into DAN-Family-Mediated BMP Antagonism.

Nolan K, Kattamuri C, Rankin SA, Read RJ, Zorn AM, Thompson TB.

Cell Rep. 2016 Aug 23;16(8):2077-2086. doi: 10.1016/j.celrep.2016.07.046. Epub 2016 Aug 11.

19.

BMP Antagonist Gremlin 2 Limits Inflammation After Myocardial Infarction.

Sanders LN, Schoenhard JA, Saleh MA, Mukherjee A, Ryzhov S, McMaster WG Jr, Nolan K, Gumina RJ, Thompson TB, Magnuson MA, Harrison DG, Hatzopoulos AK.

Circ Res. 2016 Jul 22;119(3):434-49. doi: 10.1161/CIRCRESAHA.116.308700. Epub 2016 Jun 9.

20.

Biochemistry and Biology of GDF11 and Myostatin: Similarities, Differences, and Questions for Future Investigation.

Walker RG, Poggioli T, Katsimpardi L, Buchanan SM, Oh J, Wattrus S, Heidecker B, Fong YW, Rubin LL, Ganz P, Thompson TB, Wagers AJ, Lee RT.

Circ Res. 2016 Apr 1;118(7):1125-41; discussion 1142. doi: 10.1161/CIRCRESAHA.116.308391. Review.

21.

An Evaluation of the Crystal Structure of C-terminal Truncated Apolipoprotein A-I in Solution Reveals Structural Dynamics Related to Lipid Binding.

Melchior JT, Walker RG, Morris J, Jones MK, Segrest JP, Lima DB, Carvalho PC, Gozzo FC, Castleberry M, Thompson TB, Davidson WS.

J Biol Chem. 2016 Mar 4;291(10):5439-51. doi: 10.1074/jbc.M115.706093. Epub 2016 Jan 11.

22.

Myostatin Attenuation In Vivo Reduces Adiposity, but Activates Adipogenesis.

Li N, Yang Q, Walker RG, Thompson TB, Du M, Rodgers BD.

Endocrinology. 2016 Jan;157(1):282-91. doi: 10.1210/en.2015-1546. Epub 2015 Nov 18.

23.

Circulating Growth Differentiation Factor 11/8 Levels Decline With Age.

Poggioli T, Vujic A, Yang P, Macias-Trevino C, Uygur A, Loffredo FS, Pancoast JR, Cho M, Goldstein J, Tandias RM, Gonzalez E, Walker RG, Thompson TB, Wagers AJ, Fong YW, Lee RT.

Circ Res. 2016 Jan 8;118(1):29-37. doi: 10.1161/CIRCRESAHA.115.307521. Epub 2015 Oct 21. Erratum in: Circ Res. 2018 Jan 5;122(1):e3-e4.

24.

Acute respiratory distress syndrome in patients with and without diffuse alveolar damage: an autopsy study.

Lorente JA, Cardinal-Fernández P, Muñoz D, Frutos-Vivar F, Thille AW, Jaramillo C, Ballén-Barragán A, Rodríguez JM, Peñuelas O, Ortiz G, Blanco J, Pinheiro BV, Nin N, del Carmen Marin M, Esteban A, Thompson TB.

Intensive Care Med. 2015 Nov;41(11):1921-30. doi: 10.1007/s00134-015-4046-0. Epub 2015 Sep 18.

PMID:
26385863
25.

Role of Conserved Proline Residues in Human Apolipoprotein A-IV Structure and Function.

Deng X, Walker RG, Morris J, Davidson WS, Thompson TB.

J Biol Chem. 2015 Apr 24;290(17):10689-702. doi: 10.1074/jbc.M115.637058. Epub 2015 Mar 2.

26.

Alternative binding modes identified for growth and differentiation factor-associated serum protein (GASP) family antagonism of myostatin.

Walker RG, Angerman EB, Kattamuri C, Lee YS, Lee SJ, Thompson TB.

J Biol Chem. 2015 Mar 20;290(12):7506-16. doi: 10.1074/jbc.M114.624130. Epub 2015 Feb 5.

27.

Fibronectin-based scaffold domain proteins that bind myostatin: a patent evaluation of WO2014043344.

Walker RG, Thompson TB.

Expert Opin Ther Pat. 2015 May;25(5):619-24. doi: 10.1517/13543776.2015.1007954. Epub 2015 Jan 29.

PMID:
25632990
28.

Structure of neuroblastoma suppressor of tumorigenicity 1 (NBL1): insights for the functional variability across bone morphogenetic protein (BMP) antagonists.

Nolan K, Kattamuri C, Luedeke DM, Angerman EB, Rankin SA, Stevens ML, Zorn AM, Thompson TB.

J Biol Chem. 2015 Feb 20;290(8):4759-71. doi: 10.1074/jbc.M114.628412. Epub 2015 Jan 5.

29.

Amino acid 72 of mouse and human GDF9 mature domain is responsible for altered homodimer bioactivities but has subtle effects on GDF9:BMP15 heterodimer activities.

Peng J, Wigglesworth K, Rangarajan A, Eppig JJ, Thompson TB, Matzuk MM.

Biol Reprod. 2014 Dec;91(6):142. doi: 10.1095/biolreprod.114.123158. Epub 2014 Sep 24.

30.

The DAN family: modulators of TGF-β signaling and beyond.

Nolan K, Thompson TB.

Protein Sci. 2014 Aug;23(8):999-1012. doi: 10.1002/pro.2485. Epub 2014 Jun 2. Review.

31.

The structure of human apolipoprotein A-IV as revealed by stable isotope-assisted cross-linking, molecular dynamics, and small angle x-ray scattering.

Walker RG, Deng X, Melchior JT, Morris J, Tso P, Jones MK, Segrest JP, Thompson TB, Davidson WS.

J Biol Chem. 2014 Feb 28;289(9):5596-608. doi: 10.1074/jbc.M113.541037. Epub 2014 Jan 14.

32.

Myostatin stimulates, not inihibits, C2C12 myoblast proliferation.

Rodgers BD, Wiedeback BD, Hoversten KE, Jackson MF, Walker RG, Thompson TB.

Endocrinology. 2014 Mar;155(3):670-5. doi: 10.1210/en.2013-2107. Epub 2014 Jan 1.

33.

Activins bind and signal via bone morphogenetic protein receptor type II (BMPR2) in immortalized gonadotrope-like cells.

Rejon CA, Hancock MA, Li YN, Thompson TB, Hébert TE, Bernard DJ.

Cell Signal. 2013 Dec;25(12):2717-26. doi: 10.1016/j.cellsig.2013.09.002. Epub 2013 Sep 7.

PMID:
24018044
34.

Reply to Mottershead et al.: GDF9:BMP15 heterodimers are potent regulators of ovarian functions.

Peng J, Li Q, Wigglesworth K, Rangarajan A, Kattamuri C, Peterson RT, Eppig JJ, Thompson TB, Matzuk MM.

Proc Natl Acad Sci U S A. 2013 Jun 18;110(25):E2258. No abstract available.

35.

Structure of protein related to Dan and Cerberus: insights into the mechanism of bone morphogenetic protein antagonism.

Nolan K, Kattamuri C, Luedeke DM, Deng X, Jagpal A, Zhang F, Linhardt RJ, Kenny AP, Zorn AM, Thompson TB.

Structure. 2013 Aug 6;21(8):1417-29. doi: 10.1016/j.str.2013.06.005. Epub 2013 Jul 11.

36.

Development of a small-molecule screening method for inhibitors of cellular response to myostatin and activin A.

Cash JN, Angerman EB, Kirby RJ, Merck L, Seibel WL, Wortman MD, Papoian R, Nelson S, Thompson TB.

J Biomol Screen. 2013 Aug;18(7):837-44. doi: 10.1177/1087057113482585. Epub 2013 Mar 29.

PMID:
23543431
37.

Growth differentiation factor 9:bone morphogenetic protein 15 heterodimers are potent regulators of ovarian functions.

Peng J, Li Q, Wigglesworth K, Rangarajan A, Kattamuri C, Peterson RT, Eppig JJ, Thompson TB, Matzuk MM.

Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):E776-85. doi: 10.1073/pnas.1218020110. Epub 2013 Feb 4.

38.

Small-angle X-ray scattering of apolipoprotein A-IV reveals the importance of its termini for structural stability.

Deng X, Morris J, Chaton C, Schröder GF, Davidson WS, Thompson TB.

J Biol Chem. 2013 Feb 15;288(7):4854-66. doi: 10.1074/jbc.M112.436709. Epub 2013 Jan 3.

39.

Members of the DAN family are BMP antagonists that form highly stable noncovalent dimers.

Kattamuri C, Luedeke DM, Nolan K, Rankin SA, Greis KD, Zorn AM, Thompson TB.

J Mol Biol. 2012 Dec 14;424(5):313-27. doi: 10.1016/j.jmb.2012.10.003. Epub 2012 Oct 9.

40.

Analysis of the interaction between heparin and follistatin and heparin and follistatin-ligand complexes using surface plasmon resonance.

Zhang F, Beaudet JM, Luedeke DM, Walker RG, Thompson TB, Linhardt RJ.

Biochemistry. 2012 Aug 28;51(34):6797-803. Epub 2012 Aug 13.

41.

Characterization of follistatin-type domains and their contribution to myostatin and activin A antagonism.

Cash JN, Angerman EB, Keutmann HT, Thompson TB.

Mol Endocrinol. 2012 Jul;26(7):1167-78. doi: 10.1210/me.2012-1061. Epub 2012 May 16.

42.

The structure of dimeric apolipoprotein A-IV and its mechanism of self-association.

Deng X, Morris J, Dressmen J, Tubb MR, Tso P, Jerome WG, Davidson WS, Thompson TB.

Structure. 2012 May 9;20(5):767-79. doi: 10.1016/j.str.2012.02.020.

43.

Expression and purification of recombinant protein related to DAN and cerberus (PRDC).

Kattamuri C, Luedeke DM, Thompson TB.

Protein Expr Purif. 2012 Apr;82(2):389-95. doi: 10.1016/j.pep.2012.02.010. Epub 2012 Feb 20.

44.

Improving the diffraction of apoA-IV crystals through extreme dehydration.

Deng X, Davidson WS, Thompson TB.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2012 Jan 1;68(Pt 1):105-10. doi: 10.1107/S1744309111048706. Epub 2011 Dec 24.

45.

Structure of myostatin·follistatin-like 3: N-terminal domains of follistatin-type molecules exhibit alternate modes of binding.

Cash JN, Angerman EB, Kattamuri C, Nolan K, Zhao H, Sidis Y, Keutmann HT, Thompson TB.

J Biol Chem. 2012 Jan 6;287(2):1043-53. doi: 10.1074/jbc.M111.270801. Epub 2011 Nov 3.

46.

Cytochrome b₅ reductase-cytochrome b₅ as an active P450 redox enzyme system in Phanerochaete chrysosporium: atypical properties and in vivo evidence of electron transfer capability to CYP63A2.

Syed K, Kattamuri C, Thompson TB, Yadav JS.

Arch Biochem Biophys. 2011 May 1;509(1):26-32. doi: 10.1016/j.abb.2011.02.023. Epub 2011 Mar 2.

47.

Bedside quantification of dead-space fraction using routine clinical data in patients with acute lung injury: secondary analysis of two prospective trials.

Siddiki H, Kojicic M, Li G, Yilmaz M, Thompson TB, Hubmayr RD, Gajic O.

Crit Care. 2010;14(4):R141. doi: 10.1186/cc9206. Epub 2010 Jul 29. Erratum in: Crit Care. 2011;15(2):410.

48.

The structure of myostatin:follistatin 288: insights into receptor utilization and heparin binding.

Cash JN, Rejon CA, McPherron AC, Bernard DJ, Thompson TB.

EMBO J. 2009 Sep 2;28(17):2662-76. doi: 10.1038/emboj.2009.205. Epub 2009 Jul 30.

49.

The structure of FSTL3.activin A complex. Differential binding of N-terminal domains influences follistatin-type antagonist specificity.

Stamler R, Keutmann HT, Sidis Y, Kattamuri C, Schneyer A, Thompson TB.

J Biol Chem. 2008 Nov 21;283(47):32831-8. doi: 10.1074/jbc.M801266200. Epub 2008 Sep 2.

50.

The structure of apolipoprotein A-I in high density lipoproteins.

Davidson WS, Thompson TB.

J Biol Chem. 2007 Aug 3;282(31):22249-53. Epub 2007 May 25. Review. No abstract available.

Supplemental Content

Loading ...
Support Center